Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells
Molecular Therapy · 2026-01 · 34 (1) · 281-299
DOI: 10.1016/j.ymthe.2025.09.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-01. Verfasst von Chenming Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia Athens, Athens, GA 30602, USA. Hauptthemen laut MEDLINE: Receptors, Androgen, Extracellular Vesicles, Prostatic Neoplasms, Castration-Resistant, CRISPR-Cas Systems. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, American Institute for Cancer Research.
Abstract (Originalsprache)
CRISPR-mediated gene editing is a promising technology for treatment of diseases by silencing a driver gene at the genomic DNA level. However, delivery of CRISPR machinery remains challenging for potential therapeutic application. Here, we developed a platform using extracellular vesicles (EVs) as a vehicle to deliver Cas9/single-guide RNA (sgRNA) ribonucleoprotein (RNP) complex to silence androgen receptor (AR) gene in prostate cancer (PCa) cells. A genetic modification conferred the N-myristoylation to the Cas9 protein, which enhanced the encapsulation of Cas9/sgRNA RNP into EVs and silenced both ectopic and endogenous AR gene. Interestingly, gene editing efficiency varied across PCa cell lines, associated with different chromatin accessibility at the target site. Functional analyses demonstrated that Cas9/sgRNA RNP (targeting the N-terminal domain of the AR gene) did not change gene-edited AR mRNA levels, but significantly inhibited expression levels of AR downstream genes, thereby attenuating PCa cell proliferation. Importantly, EV-mediated delivery of the Cas9/sgRNA RNP introduced indels into the AR gene and inhibited proliferation of enzalutamide-resistant PCa cells. This study highlights a therapeutic strategy for treatment of castration-resistant PCa using a programmable EV-mediated delivery platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia Athens, Athens, GA 30602, USA.
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA.
- Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA 30912, USA.
- Department of Urology, School of Medicine, Emory University, Atlanta, GA 30322, USA.
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia Athens, Athens, GA 30602, USA. Electronic address: caihj@uga.edu.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- American Institute for Cancer Research
- National Institute of Allergy and Infectious Diseases Division of Intramural Research
- Georgia Research Alliance
- National Institutes of Health
- US Army Medical Command
Zitieren
APA
Ye, C., Ma, Y., Shrestha, R., Cai, J., Liu, Y., Peng, L., Yu, J., & Cai, H. (2026). Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells. Molecular Therapy, 34(1), 281-299. https://doi.org/10.1016/j.ymthe.2025.09.045
Vancouver
Ye C, Ma Y, Shrestha R, Cai J, Liu Y, Peng L, et al. Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells. Molecular Therapy. 2026;34(1):281-299. doi:10.1016/j.ymthe.2025.09.045
BibTeX
@article{Ye2026,
author = {Ye, Chenming and Ma, Yongjie and Shrestha, Raunak and Cai, Jingwen and Liu, Yutao and Peng, Liu and Yu, Jindan and Cai, Houjian},
title = {Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {1},
pages = {281--299},
doi = {10.1016/j.ymthe.2025.09.045}
}
EUVIMED